Interestingly, the pharmacological suppression of ENT1 improved symptoms in animal models of either AD [15,25] and HD [16], indicating that the manipulation of this transporter could represent a therapeutic approach to treat neurodegenerative disorders characterized by a deregulation of adenosine homeostasis, like that occurring in NPC. Here, SLC29A1 is linked to Huntington disease.